<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996473</url>
  </required_header>
  <id_info>
    <org_study_id>19781</org_study_id>
    <secondary_id>2018-003704-39</secondary_id>
    <nct_id>NCT03996473</nct_id>
  </id_info>
  <brief_title>Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases</brief_title>
  <official_title>An Open-label, Multicenter, Phase 1/2 Study of Radium-223 Dichloride in Combination With Pembrolizumab in Participants With Stage IV Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and test the efficacy of the combination
      of radium-223 dichloride and pembrolizumab in patients with stage IV non-small cell lung
      cancer (NSCLC) with bone metastases who either have not received any systemic therapy for
      their advanced disease or have progressed on prior immunologic checkpoint blockade with
      antibodies against the programmed cell death protein-(ligand) 1 (PD-1/PD-L1). In this study
      researchers want to measure tumor shrinkage in response to treatment and how long that
      shrinkage lasts and gather information on safety. Pembrolizumab is an immunologic checkpoint
      blocker that promotes an immune response against the tumor. Radium-223 dichloride is an alpha
      particle-emitting radioactive agent which kills cancer cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) in Phase 1</measure>
    <time_frame>Until 30 days after the last dose of the study intervention (up to 4 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs) in Phase 1</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Phase 2</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) during the course of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR per RECIST v1.1 in Phase 1</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per iRECIST in Phase 1</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per RECIST v1.1 in Phase 1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DOR is defined as the time interval from the date of first response (CR or PR) to the date of disease progression or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR per iRECIST in Phase 1</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) per RECIST v1.1 in Phase 1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DCR is defined as the percentage of participants with CR or PR, or SD for at least 6 weeks during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR per iRECIST in Phase 1</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per iRECIST in Phase 2</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR per RECIST v1.1 in Phase 2</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR per iRECIST in Phase 2</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR per RECIST v1.1 in Phase 2</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR per iRECIST in Phase 2</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) per RECIST v1.1 in Phase 2</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS is defined as the time period until the date of radiological progression or death whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS per iRECIST in Phase 2</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in Phase 2</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS is defined as the time period until the death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with AE in Phase 2</measure>
    <time_frame>Until 30 days after the last dose of the study intervention (up to 5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Phase 1: Radium-223+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort 1: Radium-223+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort 1: Pembrolizumab alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive pembrolizumab every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort 2: Radium-223+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride (Xofigo, BAY 88-8223)</intervention_name>
    <description>Intravenous (IV) injection, every 6 weeks for up to 6 administrations</description>
    <arm_group_label>Phase 1: Radium-223+Pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 Cohort 1: Radium-223+Pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 Cohort 2: Radium-223+Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion, every 3 weeks for a maximum of up to 35 administrations</description>
    <arm_group_label>Phase 1: Radium-223+Pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 Cohort 1: Pembrolizumab alone</arm_group_label>
    <arm_group_label>Phase 2 Cohort 1: Radium-223+Pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 Cohort 2: Radium-223+Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of stage IV NSCLC. Phase 2 Cohort
             1: no Epidermal Growth Factor Receptor (EGFR) sensitization (activating) mutation or
             anaplastic lymphoma kinase (ALK)/ROS1 rearrangement. Treatment na√Øve (no prior
             systemic therapy) for their metastatic NSCLC. Phase 2 Cohort 2: progression on prior
             treatment with an immune checkpoint inhibitor. Phase 1 includes participants meeting
             either Cohort 1 or Cohort 2 criteria.

          -  Measurable disease per RECIST v1.1.

          -  At least 2 skeletal metastases.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

          -  Adequate bone marrow and organ function.

          -  Participants must be on a bone health agent (BHA) treatment, such as bisphosphonates
             or denosumab treatment unless such treatment is contraindicated or not recommended per
             investigator's judgement.

        Exclusion Criteria:

          -  Previous or concurrent cancer within 3 years prior to enrollment.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
             an agent directed to another stimulatory or co-inhibitory T-cell receptor. Phase 2
             Cohort 2: was discontinued from that treatment due to a Grade 3 or higher
             immune-related AEs (irAEs).

          -  Known active central nervous system metastases and/or carcinomatous meningitis.
             Participants with previously treated brain metastases may participate provided they
             are radiologically stable, clinically stable, and without requirement of steroid
             treatment for at least 14 days prior to first dose of study treatment.

          -  Active autoimmune disease that has required systemic treatment in the past 2 years.

          -  History of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Known history or presence of osteonecrosis of jaw.

          -  Ongoing infection &gt;Grade 2 NCI-CTCAE v.5.0 requiring systemic therapy.

          -  Significant acute GI disorders with diarrhea as a major symptom e.g., Crohn's disease,
             malabsorption, or ‚â• NCI-CTCAE v.5.0 Grade 2 diarrhea of any etiology.

          -  History of osteoporotic fracture.

          -  Prior treatment with radium-223 dichloride or any therapeutic radiopharmaceutical.

          -  Prior radiotherapy within 21 days of planned start of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-84 22937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Highlands Oncology Group, PA</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ccare San Marcos Cancer Center &amp; Urology</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America, Atlanta</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates, LLC</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204-2990</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology/Hematology Care (OHC) Clinical Trials, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CTCA Southwestern</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network System</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Li√®ge</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum der Johann Wolfgang Goethe Universit√§t</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Einrichtungen der Universit√§t Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt K√∂ln gGmbH - Krankenhaus Merheim</name>
      <address>
        <city>K√∂ln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Grosshansdorf</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>5810001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Parma</name>
      <address>
        <city>Parma</city>
        <state>Emilia-Romagna</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii im. Prof. Franciszka Lukaszczyka</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny UM we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catal√† d'Oncologia Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinica Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ciutat Sanit√†ria i Universitaria de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Cl√≠nic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust (Surrey)</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds teaching Hospitals</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>WF3 4PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

